<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lymphatic filariasis: Treatment and prevention</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lymphatic filariasis: Treatment and prevention</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Lymphatic filariasis: Treatment and prevention</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Amy D Klion, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter F Weller, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 24, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Filariasis is caused by nematodes (roundworms) that inhabit the lymphatics and subcutaneous tissues. Three species cause lymphatic filariasis: <em>Wuchereria bancrofti</em>, <em>Brugia malayi</em>, and <em>Brugia timori</em>. Infection is transmitted by mosquito vectors; humans are definitive hosts. Lymphatic filariasis is a major cause of disfigurement and disability in endemic areas, leading to significant economic and psychosocial impact.</p><p>The treatment and prevention of lymphatic filariasis will be reviewed here. The epidemiology, diagnosis, and clinical features of lymphatic filariasis and other filarial infections (including onchocerciasis, loiasis, and mansonellosis) are discussed separately. (See  <a class="medical medical_review" href="/d/html/5675.html" rel="external">"Lymphatic filariasis: Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5683.html" rel="external">"Onchocerciasis"</a> and  <a class="medical medical_review" href="/d/html/5684.html" rel="external">"Loiasis (Loa loa infection)"</a> and  <a class="medical medical_review" href="/d/html/83819.html" rel="external">"Mansonella infections"</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The approach to treatment of lymphatic filariasis requires an understanding of antimicrobial agent mechanisms as well as attention to the possibility of coinfection. The clinical approach is described below, followed by a discussion of data related to individual antimicrobial agents.</p><p class="headingAnchor" id="H15810528"><span class="h2">Clinical approach</span><span class="headingEndMark"> — </span>The treatment of choice for lymphatic filariasis is <a class="drug drug_general" data-topicid="112050" href="/d/drug information/112050.html" rel="external">diethylcarbamazine</a> (DEC); however, this agent is contraindicated in patients coinfected with onchocerciasis and must be used with caution in patients with loiasis, since severe adverse events can occur in individuals with high microfilarial loads  (<a class="graphic graphic_table graphicRef86736" href="/d/graphic/86736.html" rel="external">table 1</a>). In addition, variability in individual responses to DEC have been described [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/5684.html" rel="external">"Loiasis (Loa loa infection)", section on 'Treatment'</a>.)</p><p><a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">Doxycycline</a>, which targets the intracellular endosymbiont, <em>Wolbachia</em>, is an alternative first-line antifilarial therapy for nonpregnant adults and children &gt;8 years of age with lymphatic filariasis. Doxycycline has activity against adult worms and no effect on <em>L. loa</em>. Based on the available data in the literature, we favor the clinical approach discussed in the following sections.</p><p class="headingAnchor" id="H1814286832"><span class="h3">Individual treatment</span></p><p class="headingAnchor" id="H225507"><span class="h4">Monoinfection</span><span class="headingEndMark"> — </span>Patients with lymphatic filariasis (in the absence of onchocerciasis or loiasis) should receive single-dose treatment with DEC (6 mg/kg), regardless of whether clinical symptoms or microfilaremia are present [<a href="#rid2">2-4</a>]. Patients with tropical pulmonary eosinophilia due to <em>W. bancrofti</em> infection are an exception; these patients should be treated with 14 to 21 days of DEC (6 mg/kg/day). Early lymphatic changes may be present before the onset of symptoms, and reversal of early lymphatic dysfunction has been observed following DEC treatment [<a href="#rid5">5</a>].</p><p>The addition of <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (200 mg/day for four to six weeks) is also appropriate based on data demonstrating that doxycycline has macrofilaricidal activity and reduces pathology in mild to moderate disease [<a href="#rid6">6-8</a>]. Treatment is generally warranted even in the setting of advanced disease to kill any remaining adult parasites, although clinical improvement may be limited.</p><p>For cases in which DEC is not available or contraindicated, <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (200 mg/day for four to six weeks) can also be used as an alternative first line therapy.</p><p class="headingAnchor" id="H225560"><span class="h4">Concomitant infection</span><span class="headingEndMark"> — </span>DEC is contraindicated in patients coinfected with onchocerciasis and/or patients with loiasis who have high microfilarial loads due to the risk of severe adverse events.</p><p class="headingAnchor" id="H225530"><span class="h5">Onchocerciasis</span><span class="headingEndMark"> — </span>DEC is contraindicated in patients with onchocerciasis, due to the potential for severe adverse events related to killing of microfilariae in the eye and/or skin (Mazzotti reaction)  (<a class="graphic graphic_table graphicRef86736" href="/d/graphic/86736.html" rel="external">table 1</a>). Therefore, treatment of onchocerciasis with <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> (150 mcg/kg single dose) should be administered to clear <em>O. volvulus</em> microfilariae in the skin and eyes prior to standard treatment of lymphatic filariasis. (See <a class="local">'Monoinfection'</a> above.)</p><p>Based on kinetic studies of microfilarial clearance from the skin following <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> administration, it seems prudent to wait approximately one month between administration of ivermectin and initiation of DEC treatment [<a href="#rid9">9,10</a>]. In patients with ocular involvement, the length of time needed to prevent exacerbation of eye disease with DEC is unknown. Consequently, alternative therapy with <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (200 mg orally once daily for four to six weeks) followed by ivermectin (150 mcg/kg orally single dose) is reasonable for treatment of both infections; however, the efficacy of this regimen compared with standard therapy for treatment of lymphatic filariasis is not known. (See  <a class="medical medical_review" href="/d/html/5683.html" rel="external">"Onchocerciasis", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H225547"><span class="h5">Loiasis</span><span class="headingEndMark"> — </span>DEC is the treatment of choice for patients with <em>L. loa</em> coinfection and low or undetectable levels of circulating microfilariae. However, as the microfilarial load increases, the incidence of severe adverse effects (including fatal encephalopathy) related to the rapid killing of microfilariae also increases  (<a class="graphic graphic_table graphicRef86736" href="/d/graphic/86736.html" rel="external">table 1</a>). For patients with lymphatic filariasis who are coinfected with <em>L. loa</em> but have &lt;2500 <em>L. loa</em> microfilariae/mL of blood, DEC therapy using the standard regimen for loiasis (8 to 10 mg/kg/day for 21 days) should be administered. (See  <a class="medical medical_review" href="/d/html/5684.html" rel="external">"Loiasis (Loa loa infection)", section on 'Treatment'</a>.)</p><p>For patients with higher levels of <em>L. loa</em> microfilaremia (but less than 20,000 microfilariae/mL), <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> pretreatment can be used to reduce the microfilarial load prior to administration of DEC [<a href="#rid11">11,12</a>]. Patients with <em>L. loa</em> microfilarial loads greater than 20,000 microfilariae/mL should be treated with <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (200 mg orally once daily for four to six weeks), which has no effect on <em>L. loa</em>. <a class="drug drug_general" data-topicid="9371" href="/d/drug information/9371.html" rel="external">Albendazole</a> (200 to 400 mg with fatty meal twice daily for 21 days) also has no direct effect on <em>L. loa</em> microfilariae and is a reasonable alternative in patients who cannot take doxycycline. Issues related to management of high-level <em>Loa</em> microfilaremia are discussed further separately. (See  <a class="medical medical_review" href="/d/html/5684.html" rel="external">"Loiasis (Loa loa infection)", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H306745289"><span class="h3">Mass treatment</span><span class="headingEndMark"> — </span>Mass drug administration reduces the bloodborne reservoir of microfilariae to a level below that required for sustained transmission by local mosquito vectors  (<a class="graphic graphic_figure graphicRef74534" href="/d/graphic/74534.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef52000" href="/d/graphic/52000.html" rel="external">figure 2</a>). The period of microfilaremia has been estimated to be four to six years, corresponding with the reproductive lifespan of the adult parasite. <em>W. bancrofti</em> has been designated as a target for elimination since there are no animal hosts. Elimination of Brugian filariasis is not feasible since this infection has a large domestic and wild animal reservoir. (See  <a class="medical medical_review" href="/d/html/5675.html" rel="external">"Lymphatic filariasis: Epidemiology, clinical manifestations, and diagnosis", section on 'Epidemiology'</a>.)</p><p>Mass drug administration using various regimens of DEC (single dose and medicated salt), <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a>, and <a class="drug drug_general" data-topicid="9371" href="/d/drug information/9371.html" rel="external">albendazole</a> had been in place in some countries for more than 20 years prior to 2000, when the Global Program for the Elimination of Lymphatic Filariasis was launched with drug company donations of ivermectin and albendazole.</p><p>Since that time, mass drug administration programs have been implemented in more than 60 countries, with more than 5 billion doses of antifilarial therapy administered by 2014  (<a class="graphic graphic_figure graphicRef81417" href="/d/graphic/81417.html" rel="external">figure 3</a>) [<a href="#rid13">13,14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In areas where lymphatic filariasis is endemic (in the absence of onchocerciasis or loiasis), management consists of a three-drug combination regimen consisting of <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a>, <a class="drug drug_general" data-topicid="112050" href="/d/drug information/112050.html" rel="external">diethylcarbamazine</a>, and <a class="drug drug_general" data-topicid="9371" href="/d/drug information/9371.html" rel="external">albendazole</a> (single dose) or a two-drug combination regimen of diethylcarbamazine plus albendazole (administered once yearly for three years) [<a href="#rid15">15-17</a>]. </p><p></p><p class="bulletIndent1">This approach is supported by a randomized trial including more than 180 adults in Papua New Guinea with <em>W. bancrofti </em>microfilaremia treated with a single dose of the three-drug regimen, a single dose of the two-drug regimen, or the two-drug regimen administered once a year for three years [<a href="#rid16">16</a>]. Administration of the three-drug regimen was associated with clearance of microfilaremia for three years in 98 percent of participants; it was superior to the two-drug regimen administered once and noninferior to the two-drug regimen administered once a year for three years. There were no serious adverse events.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In areas where lymphatic filariasis and onchocerciasis are coendemic (in the absence of loiasis), management consists of combination therapy with yearly <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> and <a class="drug drug_general" data-topicid="9371" href="/d/drug information/9371.html" rel="external">albendazole</a>; presence of onchocerciasis precludes use of <a class="drug drug_general" data-topicid="112050" href="/d/drug information/112050.html" rel="external">diethylcarbamazine</a> [<a href="#rid18">18,19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In areas where lymphatic filariasis and loiasis are coendemic, management consists of <a class="drug drug_general" data-topicid="9371" href="/d/drug information/9371.html" rel="external">albendazole</a> monotherapy twice yearly [<a href="#rid15">15,20</a>]; unless onchocerciasis is hyperendemic, in which case the benefits of <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> for onchocerciasis are felt to outweigh the risk of serious adverse events from ivermectin treatment of loiasis, and combination therapy with yearly ivermectin and albendazole is recommended.</p><p></p><p>Suppression of transmission to &lt;1 percent (the predicted threshold for elimination) has been achieved in several countries, including Egypt, Togo, and 12 Asian and Pacific Island countries. A number of challenges remain; these include availability of funds for drug distribution and monitoring, the persistence of hot spots of transmission [<a href="#rid21">21</a>], difficulties reaching populations in remote areas and areas of conflict, and the occurrence of treatment-related encephalopathy in areas endemic for loiasis [<a href="#rid11">11,22</a>]. Human immunodeficiency virus (HIV) coinfection does not appear to affect response to mass therapy with <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> and <a class="drug drug_general" data-topicid="9371" href="/d/drug information/9371.html" rel="external">albendazole</a> [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Antimicrobial agents</span><span class="headingEndMark"> — </span>Selection of therapy for treatment of lymphatic filariasis requires an understanding of the microfilaricidal and macrofilaricidal activity of therapeutic agents. The epidemiology of other filarial diseases is also important; in regions where loiasis and onchocerciasis may coexist with lymphatic filariasis, additional consideration is important for minimizing the likelihood of adverse effects.</p><p>Most of the studies regarding the efficacy of various regimens are derived from data from mass chemotherapy programs. These data are helpful in determining the relative efficacy of the drugs and combinations in terms of microfilaricidal and macrofilaricidal activity but do not necessarily provide optimal data on management of infected individuals, particularly those who live outside of endemic areas [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H12"><span class="h3">Diethylcarbamazine</span><span class="headingEndMark"> — </span>DEC, a piperazine derivative, is a potent microfilaricidal and macrofilaricidal agent with activity against <em>W. bancrofti</em>, <em>B. malayi</em>, and <em>B. timori</em> [<a href="#rid25">25</a>]. The mechanism of action is uncertain; it is thought to alter microfilarial surface membranes or inhibit filarial release of immunomodulatory eicosanoids, thereby enhancing destruction via host immune responses [<a href="#rid26">26,27</a>]. DEC also has macrofilaricidal activity, likely via hyperpolarization leading to immobilization of adult worms. Estimates suggest DEC kills approximately 50 percent of adult worms, and its effect on adult worms in turn decreases the microfilarial burden [<a href="#rid28">28</a>].</p><p>Adverse effects of DEC include fever, headache, anorexia, nausea, and arthralgias. These effects are likely attributable to the host response following death of microfilariae (systemic reactions) and damage to adult worms (local reactions). Dying microfilariae probably release lipopolysaccharide-like proteins from endosymbiotic <em>Wolbachia</em> organisms within the filariae [<a href="#rid29">29,30</a>]. Management consists of administration of antipyretic and/or anti-inflammatory agents. Since post-DEC reactions are more severe in onchocerciasis and loiasis, evaluation for these coinfections should be pursued prior to administering DEC. (See  <a class="medical medical_review" href="/d/html/5683.html" rel="external">"Onchocerciasis"</a> and  <a class="medical medical_review" href="/d/html/5684.html" rel="external">"Loiasis (Loa loa infection)"</a>.)</p><p>DEC should be avoided in pregnancy. Animal studies have not demonstrated teratogenicity. It is not excreted in breast milk and is considered safe during lactation.</p><p>DEC is not commercially available in the United States but can be obtained from the United States Centers for Disease Control and Prevention (CDC) under an Investigational New Drug protocol (CDC Drug Service, Atlanta, GA 30333; telephone 404-718-4745) [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H15"><span class="h3">Doxycycline</span><span class="headingEndMark"> — </span>A promising alternative approach to attacking the worm directly is to focus treatment against <em>Wolbachia</em>, an intracellular bacterial symbiont of filarial parasites that is present in microfilariae and adult worms of <em>W. bancrofti</em> and both <em>Brugia</em> species [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/d/html/5675.html" rel="external">"Lymphatic filariasis: Epidemiology, clinical manifestations, and diagnosis", section on 'Wolbachia'</a>.)</p><p><a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">Doxycycline</a> has both microfilaricidal and macrofilaricidal activity and has demonstrated efficacy in both <em>W. bancrofti</em> and <em>B. malayi</em> infections [<a href="#rid33">33,34</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial including 72 Tanzanian patients with Bancroftian filariasis, patients who received <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (200 mg daily for eight weeks) had elimination of microfilaremia and diminished detectability of adult worms compared with patients who received placebo (22 versus 88 percent, respectively) [<a href="#rid35">35</a>]. Subsequent trials have demonstrated the efficacy of shorter regimens (four or six weeks may also be sufficient) [<a href="#rid24">24,36,37</a>] and that the addition of <a class="drug drug_general" data-topicid="9371" href="/d/drug information/9371.html" rel="external">albendazole</a> may enhance microfilarial clearance by doxycycline [<a href="#rid38">38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial including 161 Indonesian patients with Brugian filariasis, a six-week course of <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> reduced the prevalence of microfilaremia compared with placebo (77 versus 27 percent) [<a href="#rid39">39</a>].</p><p></p><p>There is also convincing evidence that <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> treatment, alone and in combination with DEC, reduces clinical pathology, including lymph vessel dilation and hydrocele in affected individuals [<a href="#rid6">6,7</a>]. A subsequent trial in 162 Ghanaian patients with lymphedema demonstrated that doxycycline (200 mg/day for six weeks) was effective in reducing lymphedema regardless of infection status as assessed by circulating antigen assay [<a href="#rid8">8</a>].</p><p><a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">Tetracycline</a> antibiotics may cause permanent tooth discoloration for children &lt;8 years if used repeatedly. However, <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> binds less readily to calcium than other tetracyclines and may be used for ≤21 days in children of all ages [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H1701905025"><span class="h3">Ivermectin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">Ivermectin</a> has microfilaricidal activity [<a href="#rid41">41-43</a>] but does not have significant macrofilaricidal activity [<a href="#rid44">44-47</a>]. Therefore, the reduction in microfilaremia is not sustained without repeat dosing. The clinical benefit of ivermectin is uncertain given the lack of activity against adult worms, which play an important role in the pathogenesis of lymphangitis and lymphedema. Ivermectin may have some effect in reducing the fertility of worms (in addition to its microfilaricidal activity).</p><p><a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">Ivermectin</a> is at least as effective as DEC in reducing microfilaremia due to Bancroftian filariasis [<a href="#rid48">48,49</a>]; a single dose has been shown to reduce microfilaremia by approximately 90 percent even one year after treatment [<a href="#rid41">41,42</a>]. One study in South India demonstrated that a single dose of ivermectin (150 microgram/kg) was approximately equivalent to a 12-day course of DEC in suppressing microfilaremia for three to six months [<a href="#rid50">50</a>].</p><p><a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">Ivermectin</a> is the treatment of choice for onchocerciasis and should be used as part of the regimen to treat patients with concomitant lymphatic filariasis and onchocerciasis but is contraindicated in patients with loiasis and high levels of <em>L. loa</em> microfilariae in the blood due to the risk of posttreatment encephalopathy. (See  <a class="medical medical_review" href="/d/html/5684.html" rel="external">"Loiasis (Loa loa infection)", section on 'Ivermectin'</a>.)</p><p class="headingAnchor" id="H4048391711"><span class="h3">Albendazole</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9371" href="/d/drug information/9371.html" rel="external">Albendazole</a> has no direct effect on microfilariae but leads to a slow decline in microfilaremia due to macrofilaricidal activity against the adult worms. Consequently, side effects due to rapid killing of microfilariae are not seen, and albendazole can be used in patients with concomitant loiasis or onchocerciasis. </p><p>In one study in the Democratic Republic of Congo, biannual administration of single-dose <a class="drug drug_general" data-topicid="9371" href="/d/drug information/9371.html" rel="external">albendazole</a> (400 mg) led to microfilarial clearance in 37 percent of subjects at 12 months [<a href="#rid51">51</a>] and a 94 percent reduction in the prevalence of microfilaremia after three years [<a href="#rid52">52</a>]. In addition, results from two cohort studies of repeated albendazole administration in Central Africa demonstrated a close relationship between adherence to therapy and clearance of microfilariae, further supporting this approach [<a href="#rid53">53</a>]. </p><p>Although most studies have demonstrated enhanced suppression of microfilaremia with <a class="drug drug_general" data-topicid="9371" href="/d/drug information/9371.html" rel="external">albendazole</a> and <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> as compared with ivermectin alone, albendazole does not appear to increase the microfilaricidal efficacy of DEC. In a small study that examined the effects of albendazole and DEC on adult worm killing as assessed by scrotal ultrasound, combination therapy was less effective than DEC alone [<a href="#rid54">54</a>].</p><p class="headingAnchor" id="H2825290"><span class="h2">Management of chronic pathology</span><span class="headingEndMark"> — </span>The most common chronic complications of lymphatic filariasis are recurrent lymphangitis or cellulitis, lymphedema, elephantiasis, and hydrocele. Chyluria is relatively infrequent but does occur.</p><p class="headingAnchor" id="H349462"><span class="h3">Lymphatic pathology</span><span class="headingEndMark"> — </span>Individuals with lymphedema should wash affected areas twice daily, use antibacterial creams on small abrasions, keep nails clean, and wear shoes. The affected limb should be exercised regularly to promote lymph flow and should be elevated at night. Complex decongestive physiotherapy can also be effective in some cases. The <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.lymphnet.org%2F&amp;token=vk3fn%2Ff72I9afOiTjnlxwbZSqmA4wYHnuBoeW8Ddb1yvALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=5680" target="_blank">National Lymphedema Network</a> provides a listing of certified lymphedema therapists in the United States who have expertise in treating chronic lymphedema [<a href="#rid55">55</a>]. (See  <a class="medical medical_review" href="/d/html/738.html" rel="external">"Clinical staging and conservative management of peripheral lymphedema"</a>.)</p><p>Secondary infections (especially bacterial) are contributing determinants of worsening lymphedema and elephantiasis, particularly in individuals with late-stage disease. Aggressive treatment of secondary infections and close attention to hygiene is critical. Antibiotic prophylaxis should be considered in patients who experience recurrent infections despite appropriate local care. (See  <a class="medical medical_review" href="/d/html/110530.html" rel="external">"Acute cellulitis and erysipelas in adults: Treatment"</a>.)</p><p>Reconstructive surgery involving lymphatic-venous anastomoses have been attempted to improve lymphatic drainage, but the long-term benefit is still unclear.</p><p class="headingAnchor" id="H349488"><span class="h3">Hydrocele</span><span class="headingEndMark"> — </span>The role of surgery depends upon the individual anatomy and local surgical expertise. Drainage of hydroceles may give some immediate relief but is almost always followed by reaccumulation of fluid. Hydrocelectomies can be helpful; among 301 patients with filariasis in Nigeria, hydrocelectomy was performed safely even in a rural area [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H349555"><span class="h3">Chyluria</span><span class="headingEndMark"> — </span>Chyluria may be associated with secondary nutritional deficiency. In such cases, low-fat, high-protein diets supplemented with medium-chain triglycerides can be helpful.</p><p class="headingAnchor" id="H21"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>The focus of disease control has been mass drug administration programs [<a href="#rid25">25,57,58</a>]. (See <a class="local">'Mass treatment'</a> above.)</p><p>Vector control with insecticide-treated bed nets is also a valuable tool for <em>W. bancrofti</em> elimination in areas where anopheline mosquitoes transmit the parasite [<a href="#rid59">59</a>] along with other personal protection measures against mosquitoes (eg, repellents). (See  <a class="medical medical_review" href="/d/html/4085.html" rel="external">"Prevention of arthropod and insect bites: Repellents and other measures"</a>.)</p><p>There is no vaccine available; attempts to develop effective vaccination are underway [<a href="#rid60">60</a>].</p><p class="headingAnchor" id="H3731990"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with lymphatic filariasis (in the absence of onchocerciasis or loiasis) should receive treatment with <a class="drug drug_general" data-topicid="112050" href="/d/drug information/112050.html" rel="external">diethylcarbamazine</a> (DEC), regardless of whether clinical symptoms or microfilaremia are present. The addition of <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (200 mg/day for four to six weeks) following DEC treatment is also appropriate based on data demonstrating that doxycycline has macrofilaricidal activity and reduces pathology in mild to moderate disease. Doxycycline (200 mg/day for four to six weeks) can also be used as an alternative first line therapy in cases where DEC is not available or contraindicated. (See <a class="local">'Monoinfection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with coinfection due to lymphatic filariasis and onchocerciasis (in the absence of evidence for eye involvement) should undergo treatment of onchocerciasis first, with <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> (150 mcg/kg single dose) alone, followed by standard treatment for lymphatic filariasis  (<a class="graphic graphic_table graphicRef86736" href="/d/graphic/86736.html" rel="external">table 1</a>). In patients with eye involvement, <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (200 mg orally once daily for four to six weeks) followed by ivermectin (150 mcg/kg orally single dose) can be used, although the relative efficacy of this regimen compared with the standard DEC-containing regimen is not known. (See <a class="local">'Onchocerciasis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The approach to patients with concomitant infection due to lymphatic filariasis and loiasis depends on the level of circulating <em>L. loa</em> microfilaremia  (<a class="graphic graphic_table graphicRef86736" href="/d/graphic/86736.html" rel="external">table 1</a>). For patients with &lt;2500 <em>L. loa</em> microfilariae/mL of blood, DEC therapy using the standard regimen for loiasis (8 to 10 mg/kg/day for 21 days) should be administered. For patients with &gt;2500 but &lt;20,000 <em>L. loa</em> microfilariae/mL of blood, <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a> can be used to decrease the <em>L. loa</em> mf load prior to DEC treatment. For patients with &gt;20,000 <em>L. loa</em> microfilariae/mL of blood, <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (200 mg orally once daily for four to six weeks), which has no effect on <em>L. loa</em>, is the treatment of choice for the lymphatic filariasis. <a class="drug drug_general" data-topicid="9371" href="/d/drug information/9371.html" rel="external">Albendazole</a> (200 to 400 mg with fatty meal twice daily for 21 days) has no direct effect on <em>L. loa</em> microfilariae and is a reasonable alternative in patients who cannot take doxycycline. Issues related to management of high-level <em>Loa</em> microfilaremia are discussed further separately. (See <a class="local">'Loiasis'</a> above and  <a class="medical medical_review" href="/d/html/5684.html" rel="external">"Loiasis (Loa loa infection)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Management of chronic complications of lymphatic filariasis is an important component of therapy. Secondary (often bacterial) infections are contributing determinants of worsening lymphedema and elephantiasis, particularly in individuals with late-stage disease. Aggressive treatment of secondary infections and close attention to hygiene is critical. Individuals with lymphedema should wash affected areas twice daily, use antibacterial creams on small abrasions, keep nails clean, and wear shoes. The affected limb should be exercised regularly to promote lymph flow and should be elevated at night. Prophylactic antibiotics may be necessary in some cases. Hydrocelectomy can be useful in reducing morbidity in affected patients. (See <a class="local">'Management of chronic pathology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mass drug administration reduces the bloodborne reservoir of microfilariae to a level below that required for sustained transmission by local mosquito vectors. Programs have been initiated in more than 60 countries and use various combinations of <a class="drug drug_general" data-topicid="9371" href="/d/drug information/9371.html" rel="external">albendazole</a>, <a class="drug drug_general" data-topicid="8641" href="/d/drug information/8641.html" rel="external">ivermectin</a>, and DEC. These programs have led to suppression of transmission to &lt;1 percent (the predicted threshold for elimination) in several countries; many challenges remain. (See <a class="local">'Mass treatment'</a> above.)</p><p></p><p class="headingAnchor" id="H373863575"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Dr. Karin Leder, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sankari T, Subramanian S, Hoti SL, et al. Heterogeneous response of Wuchereria bancrofti-infected persons to diethylcarbamazine (DEC) and its implications for the Global Programme to Eliminate Lymphatic Filariasis (GPELF). Parasitol Res 2021; 120:311.</a></li><li class="breakAll">United States Centers for Disease Control and Prevention. Parasites - Lymphatic Filariasis. http://www.cdc.gov/parasites/lymphaticfilariasis/treatment.html (Accessed on July 01, 2013).</li><li><a class="nounderline abstract_t">Cartel JL, Celerier P, Spiegel A, et al. A single diethylcarbamazine dose for treatment of Wuchereria bancrofti carriers in French Polynesia: efficacy and side effects. Southeast Asian J Trop Med Public Health 1990; 21:465.</a></li><li><a class="nounderline abstract_t">Andrade LD, Medeiros Z, Pires ML, et al. Comparative efficacy of three different diethylcarbamazine regimens in lymphatic filariasis. Trans R Soc Trop Med Hyg 1995; 89:319.</a></li><li><a class="nounderline abstract_t">Moore TA, Reynolds JC, Kenney RT, et al. Diethylcarbamazine-induced reversal of early lymphatic dysfunction in a patient with bancroftian filariasis: assessment with use of lymphoscintigraphy. Clin Infect Dis 1996; 23:1007.</a></li><li><a class="nounderline abstract_t">Debrah AY, Mand S, Marfo-Debrekyei Y, et al. Reduction in levels of plasma vascular endothelial growth factor-A and improvement in hydrocele patients by targeting endosymbiotic Wolbachia sp. in Wuchereria bancrofti with doxycycline. Am J Trop Med Hyg 2009; 80:956.</a></li><li><a class="nounderline abstract_t">Mand S, Pfarr K, Sahoo PK, et al. Macrofilaricidal activity and amelioration of lymphatic pathology in bancroftian filariasis after 3 weeks of doxycycline followed by single-dose diethylcarbamazine. Am J Trop Med Hyg 2009; 81:702.</a></li><li><a class="nounderline abstract_t">Mand S, Debrah AY, Klarmann U, et al. Doxycycline improves filarial lymphedema independent of active filarial infection: a randomized controlled trial. Clin Infect Dis 2012; 55:621.</a></li><li><a class="nounderline abstract_t">Greene BM, Taylor HR, Cupp EW, et al. Comparison of ivermectin and diethylcarbamazine in the treatment of onchocerciasis. N Engl J Med 1985; 313:133.</a></li><li><a class="nounderline abstract_t">Lariviere M, Vingtain P, Aziz M, et al. Double-blind study of ivermectin and diethylcarbamazine in African onchocerciasis patients with ocular involvement. Lancet 1985; 2:174.</a></li><li><a class="nounderline abstract_t">Gardon J, Gardon-Wendel N, Demanga-Ngangue, et al. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet 1997; 350:18.</a></li><li><a class="nounderline abstract_t">Kamgno J, Pion SD, Chesnais CB, et al. A Test-and-Not-Treat Strategy for Onchocerciasis in Loa loa-Endemic Areas. N Engl J Med 2017; 377:2044.</a></li><li><a class="nounderline abstract_t">Hopkins DR. Disease eradication. N Engl J Med 2013; 368:54.</a></li><li><a class="nounderline abstract_t">489 Global programme to eliminate lymphatic filariasis: progress report, 2014. Wkly Epidemiol Rec 2015; 90:489.</a></li><li class="breakAll">World Health Organization. Guideline for alternative mass drug administration regimens to eliminate lyphatic filariasis, 2017. http://www.who.int/lymphatic_filariasis/resources/9789241550161/en/ (Accessed on November 20, 2017).</li><li><a class="nounderline abstract_t">King CL, Suamani J, Sanuku N, et al. A Trial of a Triple-Drug Treatment for Lymphatic Filariasis. N Engl J Med 2018; 379:1801.</a></li><li><a class="nounderline abstract_t">Hast MA, Tufa A, Brant TA, et al. Notes from the Field: Impact of a Mass Drug Administration Campaign Using a Novel Three-Drug Regimen on Lymphatic Filariasis Antigenemia - American Samoa, 2019. MMWR Morb Mortal Wkly Rep 2020; 69:656.</a></li><li><a class="nounderline abstract_t">Thomsen EK, Sanuku N, Baea M, et al. Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis. Clin Infect Dis 2016; 62:334.</a></li><li><a class="nounderline abstract_t">Fischer PU, King CL, Jacobson JA, Weil GJ. Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa. PLoS Negl Trop Dis 2017; 11:e0005163.</a></li><li><a class="nounderline abstract_t">Ouattara AF, Bjerum CM, Aboulaye M, et al. Semiannual Treatment of Albendazole Alone is Efficacious for Treatment of Lymphatic Filariasis: A Randomized Open-label Trial in Cote d'Ivoire. Clin Infect Dis 2022; 74:2200.</a></li><li><a class="nounderline abstract_t">Rao RU, Samarasekera SD, Nagodavithana KC, et al. Comprehensive Assessment of a Hotspot with Persistent Bancroftian Filariasis in Coastal Sri Lanka. Am J Trop Med Hyg 2018; 99:735.</a></li><li><a class="nounderline abstract_t">Twum-Danso NA. Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future. Filaria J 2003; 2 Suppl 1:S7.</a></li><li><a class="nounderline abstract_t">Kroidl I, Saathof E, Maganga L, et al. Prevalence of Lymphatic Filariasis and Treatment Effectiveness of Albendazole/ Ivermectin in Individuals with HIV Co-infection in Southwest-Tanzania. PLoS Negl Trop Dis 2016; 10:e0004618.</a></li><li><a class="nounderline abstract_t">Hoerauf A. Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis. Curr Opin Infect Dis 2008; 21:673.</a></li><li><a class="nounderline abstract_t">Tisch DJ, Michael E, Kazura JW. Mass chemotherapy options to control lymphatic filariasis: a systematic review. Lancet Infect Dis 2005; 5:514.</a></li><li><a class="nounderline abstract_t">Frayha GJ, Smyth JD, Gobert JG, Savel J. The mechanisms of action of antiprotozoal and anthelmintic drugs in man. Gen Pharmacol 1997; 28:273.</a></li><li><a class="nounderline abstract_t">Maizels RM, Bundy DA, Selkirk ME, et al. Immunological modulation and evasion by helminth parasites in human populations. Nature 1993; 365:797.</a></li><li><a class="nounderline abstract_t">Klion AD, Ottesen EA, Nutman TB. Effectiveness of diethylcarbamazine in treating loiasis acquired by expatriate visitors to endemic regions: long-term follow-up. J Infect Dis 1994; 169:604.</a></li><li><a class="nounderline abstract_t">Hise AG, Gillette-Ferguson I, Pearlman E. The role of endosymbiotic Wolbachia bacteria in filarial disease. Cell Microbiol 2004; 6:97.</a></li><li><a class="nounderline abstract_t">Taylor MJ, Cross HF, Bilo K. Inflammatory responses induced by the filarial nematode Brugia malayi are mediated by lipopolysaccharide-like activity from endosymbiotic Wolbachia bacteria. J Exp Med 2000; 191:1429.</a></li><li class="breakAll">Centers for Disease Control and Prevention - Parasites. www.cdc.gov/ncidod/dpd/professional/drgsrv_drug_table.htm (Accessed on December 11, 2009).</li><li><a class="nounderline abstract_t">Stolk WA, de Vlas SJ, Habbema JD. Anti-Wolbachia treatment for lymphatic filariasis. Lancet 2005; 365:2067.</a></li><li><a class="nounderline abstract_t">Hoerauf A, Volkmann L, Hamelmann C, et al. Endosymbiotic bacteria in worms as targets for a novel chemotherapy in filariasis. Lancet 2000; 355:1242.</a></li><li><a class="nounderline abstract_t">Taylor MJ. Wolbachia bacteria of filarial nematodes in the pathogenesis of disease and as a target for control. Trans R Soc Trop Med Hyg 2000; 94:596.</a></li><li><a class="nounderline abstract_t">Taylor MJ, Makunde WH, McGarry HF, et al. Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial. Lancet 2005; 365:2116.</a></li><li><a class="nounderline abstract_t">Debrah AY, Mand S, Specht S, et al. Doxycycline reduces plasma VEGF-C/sVEGFR-3 and improves pathology in lymphatic filariasis. PLoS Pathog 2006; 2:e92.</a></li><li><a class="nounderline abstract_t">Debrah AY, Mand S, Marfo-Debrekyei Y, et al. Macrofilaricidal effect of 4 weeks of treatment with doxycycline on Wuchereria bancrofti. Trop Med Int Health 2007; 12:1433.</a></li><li><a class="nounderline abstract_t">Gayen P, Nayak A, Saini P, et al. A double-blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta Trop 2013; 125:150.</a></li><li><a class="nounderline abstract_t">Supali T, Djuardi Y, Pfarr KM, et al. Doxycycline treatment of Brugia malayi-infected persons reduces microfilaremia and adverse reactions after diethylcarbamazine and albendazole treatment. Clin Infect Dis 2008; 46:1385.</a></li><li class="breakAll">American Academy of Pediatrics. Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32 ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021.</li><li><a class="nounderline abstract_t">Cao WC, Van der Ploeg CP, Plaisier AP, et al. Ivermectin for the chemotherapy of bancroftian filariasis: a meta-analysis of the effect of single treatment. Trop Med Int Health 1997; 2:393.</a></li><li><a class="nounderline abstract_t">Addiss DG, Beach MJ, Streit TG, et al. Randomised placebo-controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet 1997; 350:480.</a></li><li><a class="nounderline abstract_t">Shenoy RK, Kumaraswami V, Rajan K, et al. Ivermectin for the treatment of periodic malayan filariasis: a study of efficacy and side effects following a single oral dose and retreatment at six months. Ann Trop Med Parasitol 1992; 86:271.</a></li><li><a class="nounderline abstract_t">Nicolas L, Plichart C, Nguyen LN, Moulia-Pelat JP. Reduction of Wuchereria bancrofti adult worm circulating antigen after annual treatments of diethylcarbamazine combined with ivermectin in French Polynesia. J Infect Dis 1997; 175:489.</a></li><li><a class="nounderline abstract_t">Weil GJ, Lammie PJ, Richards FO Jr, Eberhard ML. Changes in circulating parasite antigen levels after treatment of bancroftian filariasis with diethylcarbamazine and ivermectin. J Infect Dis 1991; 164:814.</a></li><li><a class="nounderline abstract_t">Dreyer G, Noroes J, Amaral F, et al. Direct assessment of the adulticidal efficacy of a single dose of ivermectin in bancroftian filariasis. Trans R Soc Trop Med Hyg 1995; 89:441.</a></li><li><a class="nounderline abstract_t">Kazura JW. Ivermectin and human lymphatic filariasis. Microb Pathog 1993; 14:337.</a></li><li><a class="nounderline abstract_t">Ottesen EA, Campbell WC. Ivermectin in human medicine. J Antimicrob Chemother 1994; 34:195.</a></li><li><a class="nounderline abstract_t">Chodakewitz J. Ivermectin and Lymphatic Filariasis: A Clinical Update. Parasitol Today 1995; 11:233.</a></li><li><a class="nounderline abstract_t">Ottesen EA, Vijayasekaran V, Kumaraswami V, et al. A controlled trial of ivermectin and diethylcarbamazine in lymphatic filariasis. N Engl J Med 1990; 322:1113.</a></li><li><a class="nounderline abstract_t">Pion SD, Chesnais CB, Bopda J, et al. The impact of two semiannual treatments with albendazole alone on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in the Republic of Congo. Am J Trop Med Hyg 2015; 92:959.</a></li><li><a class="nounderline abstract_t">Pion SDS, Chesnais CB, Weil GJ, et al. Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo. Lancet Infect Dis 2017; 17:763.</a></li><li><a class="nounderline abstract_t">Campillo JT, Awaca-Uvon NP, Missamou F, et al. Results From 2 Cohort Studies in Central Africa Show That Clearance of Wuchereria bancrofti Infection After Repeated Rounds of Mass Drug Administration With Albendazole Alone Is Closely Linked to Individual Adherence. Clin Infect Dis 2021; 73:e176.</a></li><li><a class="nounderline abstract_t">Dreyer G, Addiss D, Williamson J, Norões J. Efficacy of co-administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti. Trans R Soc Trop Med Hyg 2006; 100:1118.</a></li><li class="breakAll">National Lymphedema Network. http://www.lymphnet.org (Accessed on January 28, 2013).</li><li><a class="nounderline abstract_t">Thomas G, Richards FO Jr, Eigege A, et al. A pilot program of mass surgery weeks for treatment of hydrocele due to lymphatic filariasis in central Nigeria. Am J Trop Med Hyg 2009; 80:447.</a></li><li><a class="nounderline abstract_t">Ottesen EA. Major progress toward eliminating lymphatic filariasis. N Engl J Med 2002; 347:1885.</a></li><li><a class="nounderline abstract_t">Global Programme to Eliminate Lymphatic Filariasis. Wkly Epidemiol Rec 2006; 81:221.</a></li><li><a class="nounderline abstract_t">Reimer LJ, Thomsen EK, Tisch DJ, et al. Insecticidal bed nets and filariasis transmission in Papua New Guinea. N Engl J Med 2013; 369:745.</a></li><li><a class="nounderline abstract_t">Grieve RB, Wisnewski N, Frank GR, Tripp CA. Vaccine research and development for the prevention of filarial nematode infections. Pharm Biotechnol 1995; 6:737.</a></li></ol></div><div id="topicVersionRevision">Topic 5680 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33146778" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Heterogeneous response of Wuchereria bancrofti-infected persons to diethylcarbamazine (DEC) and its implications for the Global Programme to Eliminate Lymphatic Filariasis (GPELF).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33146778" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Heterogeneous response of Wuchereria bancrofti-infected persons to diethylcarbamazine (DEC) and its implications for the Global Programme to Eliminate Lymphatic Filariasis (GPELF).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2075489" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A single diethylcarbamazine dose for treatment of Wuchereria bancrofti carriers in French Polynesia: efficacy and side effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7660449" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Comparative efficacy of three different diethylcarbamazine regimens in lymphatic filariasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8922794" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Diethylcarbamazine-induced reversal of early lymphatic dysfunction in a patient with bancroftian filariasis: assessment with use of lymphoscintigraphy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19478258" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Reduction in levels of plasma vascular endothelial growth factor-A and improvement in hydrocele patients by targeting endosymbiotic Wolbachia sp. in Wuchereria bancrofti with doxycycline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19815891" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Macrofilaricidal activity and amelioration of lymphatic pathology in bancroftian filariasis after 3 weeks of doxycycline followed by single-dose diethylcarbamazine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22610930" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Doxycycline improves filarial lymphedema independent of active filarial infection: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3892293" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Comparison of ivermectin and diethylcarbamazine in the treatment of onchocerciasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2862370" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Double-blind study of ivermectin and diethylcarbamazine in African onchocerciasis patients with ocular involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9217715" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29116890" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : A Test-and-Not-Treat Strategy for Onchocerciasis in Loa loa-Endemic Areas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23281976" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Disease eradication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26387149" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : 489 Global programme to eliminate lymphatic filariasis: progress report, 2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26387149" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : 489 Global programme to eliminate lymphatic filariasis: progress report, 2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30403937" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A Trial of a Triple-Drug Treatment for Lymphatic Filariasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32463808" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Notes from the Field: Impact of a Mass Drug Administration Campaign Using a Novel Three-Drug Regimen on Lymphatic Filariasis Antigenemia - American Samoa, 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26486704" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28056015" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33674871" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Semiannual Treatment of Albendazole Alone is Efficacious for Treatment of Lymphatic Filariasis: A Randomized Open-label Trial in Cote d'Ivoire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30014812" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Comprehensive Assessment of a Hotspot with Persistent Bancroftian Filariasis in Coastal Sri Lanka.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14975064" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27070786" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Prevalence of Lymphatic Filariasis and Treatment Effectiveness of Albendazole/ Ivermectin in Individuals with HIV Co-infection in Southwest-Tanzania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18978537" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16048720" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Mass chemotherapy options to control lymphatic filariasis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9013207" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The mechanisms of action of antiprotozoal and anthelmintic drugs in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8413664" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Immunological modulation and evasion by helminth parasites in human populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8158033" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Effectiveness of diethylcarbamazine in treating loiasis acquired by expatriate visitors to endemic regions: long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14706096" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The role of endosymbiotic Wolbachia bacteria in filarial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10770808" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Inflammatory responses induced by the filarial nematode Brugia malayi are mediated by lipopolysaccharide-like activity from endosymbiotic Wolbachia bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10770808" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Inflammatory responses induced by the filarial nematode Brugia malayi are mediated by lipopolysaccharide-like activity from endosymbiotic Wolbachia bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15964428" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Anti-Wolbachia treatment for lymphatic filariasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10770311" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Endosymbiotic bacteria in worms as targets for a novel chemotherapy in filariasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11198638" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Wolbachia bacteria of filarial nematodes in the pathogenesis of disease and as a target for control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15964448" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17044733" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Doxycycline reduces plasma VEGF-C/sVEGFR-3 and improves pathology in lymphatic filariasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18076549" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Macrofilaricidal effect of 4 weeks of treatment with doxycycline on Wuchereria bancrofti.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23123345" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A double-blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18419441" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Doxycycline treatment of Brugia malayi-infected persons reduces microfilaremia and adverse reactions after diethylcarbamazine and albendazole treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18419441" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Doxycycline treatment of Brugia malayi-infected persons reduces microfilaremia and adverse reactions after diethylcarbamazine and albendazole treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9171850" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Ivermectin for the chemotherapy of bancroftian filariasis: a meta-analysis of the effect of single treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9274584" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Randomised placebo-controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1449275" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Ivermectin for the treatment of periodic malayan filariasis: a study of efficacy and side effects following a single oral dose and retreatment at six months.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9203681" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Reduction of Wuchereria bancrofti adult worm circulating antigen after annual treatments of diethylcarbamazine combined with ivermectin in French Polynesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1894943" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Changes in circulating parasite antigen levels after treatment of bancroftian filariasis with diethylcarbamazine and ivermectin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7570894" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Direct assessment of the adulticidal efficacy of a single dose of ivermectin in bancroftian filariasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8366812" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Ivermectin and human lymphatic filariasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7814280" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Ivermectin in human medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Ivermectin and Lymphatic Filariasis: A Clinical Update</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2181312" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A controlled trial of ivermectin and diethylcarbamazine in lymphatic filariasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25758650" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The impact of two semiannual treatments with albendazole alone on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in the Republic of Congo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28372977" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32856050" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Results From 2 Cohort Studies in Central Africa Show That Clearance of Wuchereria bancrofti Infection After Repeated Rounds of Mass Drug Administration With Albendazole Alone Is Closely Linked to Individual Adherence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16860830" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Efficacy of co-administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16860830" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Efficacy of co-administered diethylcarbamazine and albendazole against adult Wuchereria bancrofti.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19270297" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A pilot program of mass surgery weeks for treatment of hydrocele due to lymphatic filariasis in central Nigeria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12466515" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Major progress toward eliminating lymphatic filariasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16749186" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Global Programme to Eliminate Lymphatic Filariasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23964936" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Insecticidal bed nets and filariasis transmission in Papua New Guinea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7551246" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Vaccine research and development for the prevention of filarial nematode infections.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
